GeneTex, Inc.
6.6.2023 15:05:40 CEST | ACCESS Newswire | Press release
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
FQ-42 Vengeance Finds New Home at Creech Air Force Base21.9.2026 17:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / September 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) congratulates the U.S. Air Force (USAF) on the pace of progress for its Collaborative Combat Aircraft program, which features the FQ-42 Vengeance designed and produced by GA-ASI. The latest milestone took place Sept. 18, when a new FQ-42 Vengeance was delivered to Creech AFB, Nev., to continue operations with test and evaluation units. "The CCA program's rate of progress has been incredible," said Mike Atwood, GA-ASI Vice President of Advanced Programs. "Every week, the Air Force is pushing forward with new and more impressive accomplishments using Vengeance. It's amazing to think of how far this program has come in such a short amount of time." The FQ-42 that arrived at Creech will continue regular test and evaluation operations with the Air Force aimed at experimentation with the new aircraft. Previous efforts with Vengeance and other GA-ASI jets, including XQ-67A Off-Board Sens
Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine21.9.2026 15:45:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced Dream Bowl XV. The game is the 15th anniversary edition of the premier college football all-star showcase for professional draft-eligible talent from all college divisions and NAIA programs. It will be held Sunday, January 17, 2027, at AT&T Stadium in Arlington, Texas, and is planned to be broadcast nationally on ESPN. Dream Bowl XV continues Datavault AI's role as an intellectual property licensing partner and official sponsor of The Dream Bowl alongside Cutting-Edge Sports Management. It builds on the Company's debut at Dream Bowl XIV. Since 2013, The Dream Bowl has honored the legacy of Dr. Martin Luther King Jr. and has given overlooked collegiate athletes a professional-caliber send-off in front of professional scouts. N
Winners of this Year's Semmelweis-Richter International Journalism Award Announced21.9.2026 14:05:00 CEST | Press release
BUDAPEST I. KERÜLET, HU / ACCESS Newswire / September 21, 2026 / For the second time, Semmelweis University, with the support of Gedeon Richter, has recognized outstanding health and science journalism from across Europe through the Semmelweis-Richter Journalism Award. Six entries received awards in the "Women's Health" and "Pharmaceutical Strategies and Innovation" categories. The first prizes in the two categories were awarded to an international investigative project on abortion and an article about a technology that uses miniature bioengineered devices to mimic the functions of human organs. The competition received around 60 entries from nearly 20 countries. The Semmelweis-Richter Journalism Award was established to recognize high-quality health and science journalism in Europe. As last year, the competition attracted entries from journalists working for major international media outlets, including The Guardian, the Financial Times, The Times, BBC News, Süddeutsche Zeitung and Púb
NOVELIC Partners with Global DMS Leader Smart Eye to Develop Next-Generation Camera and Radar In-Cabin Monitoring Systems21.9.2026 08:00:00 CEST | Press release
BELGRADE, RS / ACCESS Newswire / September 21, 2026 / NOVELIC, a Belgrade-based innovator in mmWave radar solutions, announced a strategic partnership with Smart Eye, a global leader in Driver Monitoring Systems (DMS) and Interior Sensing AI, to provide OEMs with a well-rounded feature set that satisfies the upcoming Euro NCAP requirements for driver and occupant monitoring. The result is a scalable and cost-effective solution that combines vision and radar for straightforward integration. Since the software is running entirely on the sensor, only a single CAN-Bus interface to the vehicle is required, eliminating the need for external hardware, LVDS interfaces, and added computational load elsewhere in the car. NOVELIC and Smart Eye's innovative system approach will debut at Smart Eye's booth #305 at InCabin Europe 2026 in Barcelona. The demonstration will showcase enhanced performance and compliance with relevant safety protocols through the fusion of radar and vision technologies. NO
Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner17.9.2026 14:50:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / September 17, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ali Palmer as a Partner in the firm's Human Resources Practice. Based in London, Palmer advises boards, chief executive officers and chief people officers on the recruitment of senior human resources leaders, helping organizations build leadership teams that enable growth, transformation and long-term performance. Ali Palmer, Partner in Caldwell's Human Resources Practice. With more than 20 years of executive search and leadership advisory experience, Palmer partners with listed companies, private equity-backed businesses and privately held organizations across a broad range of sectors, with particular expertise in consumer, retail, industrial, financial services, pharmaceutical and technology. She leads executive search assignments across the full human resources function, from chief people officers and chief human resources
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom